Segment Reporting

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Segment Reporting

(14)

Segment Reporting

In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single business segment, which is the development and commercialization of therapeutic and diagnostic products that service women’s reproductive health needs (infertility and permanent birth control).

The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). As a single reportable segment entity, the Company’s segment performance measure is net loss attributable to shareholders. The measurement of segment assets is reported on the balance sheet as total assets. The Company’s CODM is its Chief Executive Officer and Chief Financial Officer, who together review and evaluate net income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

Significant segment expenses, as provided to the CODM are as follows:

	Three Months Ended June 30,					Six Months Ended June 30,
		2025		2024			2025		2024
Sales	$	409,268		221,484			750,532		492,624
Cost of sales (excluding depreciation expense)		158,171		73,125			275,437		161,657
Research and development expense		89,217		665,517			1,048,380		1,080,780
Other research and development expense1		1,325,212		1,310,358			3,334,521		2,665,826
Total research and development expense		1,414,429		1,975,875			4,382,901		3,746,606
Sales and marketing expense		984,977		975,190			1,893,544		1,275,677
General and administrative expense		1,616,972		1,611,817			3,339,685		3,114,621
Depreciation and amortization expense		86,285		67,628			171,138		138,856
Total operating expenses		4,102,663		4,630,510			9,787,268		8,275,760
Total other expense, net		(734,356	)	(204,173	)		(1,174,776	)	(341,041	)
Loss before income taxes		(4,585,922	)	(4,686,324	)		(10,486,949	)	(8,285,834	)
Income tax benefit		—		(1,750	)		(4,188	)	(1,750	)
Net loss		(4,585,922	)	(4,684,574	)		(10,482,761	)	(8,284,084	)

¹ Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.